Migraine history and breast cancer risk among postmenopausal women. 2010

Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
Fred Hutchinson Cancer Research Center, 1100 N Fairview Ave, M4-C308, Seattle, WA 98109-1024, USA. cili@fhcrc.org

PURPOSE Both migraine and breast cancer are hormonally mediated. Two recent reports indicate that women with a migraine history may have a lower risk of postmenopausal breast cancer than those who never suffered migraines. This finding requires confirmation; in particular, an assessment of the influence of use of nonsteroidal anti-inflammatory drugs (NSAID) is needed, because many studies indicate that NSAID use also may confer a reduction in breast cancer risk. METHODS We assessed the relationship between self-reported history of migraine and incidence of postmenopausal breast cancer in 91,116 women enrolled on the Women's Health Initiative Observational Study prospective cohort from 1993 to 1998 at ages 50 to 79 years. Through September 15, 2005, there were 4,006 eligible patients with breast cancer diagnosed. Results Women with a history of migraine had a lower risk of breast cancer (hazard ratio [HR], 0.89; 95% CI, 0.80 to 98) than women without a migraine history. This risk did not vary by recent NSAID use. The lower risk was somewhat more pronounced for invasive estrogen-receptor-positive and progesterone-receptor-positive tumors (HR, 0.83; 95% CI, 0.71 to 0.97), as no reduction in risk was observed for invasive ER-negative/PR-negative tumors (HR, 1.16; 95% CI, 0.86 to 1.57), and this difference in risk estimates was borderline statistically significant (P = .06). CONCLUSION This study supports the hypothesis that a history of migraine is associated with a lower risk of breast cancer and that this relationship is independent of recent NSAID use.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008881 Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1) Acute Confusional Migraine,Headache, Migraine,Status Migrainosus,Abdominal Migraine,Cervical Migraine Syndrome,Hemicrania Migraine,Migraine,Migraine Headache,Migraine Variant,Sick Headache,Abdominal Migraines,Acute Confusional Migraines,Cervical Migraine Syndromes,Disorder, Migraine,Disorders, Migraine,Headache, Sick,Headaches, Migraine,Headaches, Sick,Hemicrania Migraines,Migraine Disorder,Migraine Headaches,Migraine Syndrome, Cervical,Migraine Syndromes, Cervical,Migraine Variants,Migraine, Abdominal,Migraine, Acute Confusional,Migraine, Hemicrania,Migraines,Migraines, Abdominal,Migraines, Acute Confusional,Migraines, Hemicrania,Sick Headaches,Variant, Migraine,Variants, Migraine
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
September 2009, Epidemiology (Cambridge, Mass.),
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
August 2003, International journal of cancer,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
May 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
October 2010, Archives of internal medicine,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
May 2001, Cancer causes & control : CCC,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
March 2004, Cancer causes & control : CCC,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
April 2014, Endocrine-related cancer,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
February 1997, The New England journal of medicine,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
April 2009, International journal of cancer,
Christopher I Li, and Robert W Mathes, and Elizabeth C Bluhm, and Bette Caan, and Mary F Cavanagh, and Rowan T Chlebowski, and Yvonne Michael, and Mary Jo O'Sullivan, and Marcia L Stefanick, and Ross Prentice
February 2012, Breast cancer research and treatment,
Copied contents to your clipboard!